Table 1.
Characteristics of the study population
| Characteristics | Total group (n = 301) |
| Age1 (yr) | 48.27 ± 11.79 |
| Gender (%, M/F) | 57.5/42.5 |
| Contamination mode (%) | |
| Tranfusion | 27.2 |
| Drug-addict | 26.9 |
| Blood exposure accident | 7.6 |
| Others | 38.2 |
| Genotype (% with 1/2/3/4/5/ND) | 35/11/18/8/2/26 |
| Stage of fibrosis (% with stage 0/1/2/3/4/ND) | 1/11/42/20/20/6 |
| Type of treatment (%) | |
| With IFNα | 3.3 |
| Peg-interferon | 9.0 |
| IFNα + ribavirin | 27.2 |
| Peg-interferon + ribavirin | 60.4 |
| Duration of treatment (mo)1 | 7.91 ± 3.78 |
| TSH before treatment (MIU/L)1 | 1.54 ± 1.25 |
| Positive antibodies before treatment | |
| TPOAb | 12/229 |
| TGAb | 8/227 |
| TSHRAb | 1/95 |
ND: Not determined.
1
mean ± SD.